Liver resection for intermediate hepatocellular carcinoma

Table 1 Studies related to complications of liver resection and transhepatic arterial chemotherapy and embolization for intermediate hepatocellular carcinoma

Ref.	Patient	Median OS	Survival rate	DFS	Hospital mortality	Complications
Wang et al[24]	LR: 243	LR: 60.4	1-, 3- and 5-yr	NR	NR	NR
	TACE: 741	TACE: 18.2	LR: 81.5%, 64.4%, 50.5%
		Sig	TACE: 61.9%, 29.1%, 16.4%
			Sig
Ho et al[25]	LR: 122	LR: 41.8	1-, 3- and 5-yr	1-, 3- and 5-yr	NR	NR
	TACE: 163	TACE: 16.8	LR: 77.4%, 51.9%, 36.6%	LR: 60.5%, 32.3%, 24.8%
		Sig	TACE: 62.6%, 25.2%, 11%
			Sig
Lin et al[26]	LR: 93	LR: 27.6	1-, 2- and 3-yr	NR	LR: 3/78 (3.8%)	NR
	TACE: 73	TACE: 18.5	LR: 83%, 62%, 49%		TACE: 5/93 (5.4%)
			TACE: 39%, 5%, 2%		No sig
			Sig
Hsu et al[27]	LR: 268	NR	1-, 3- and 5-yr	NR	90 d	LR vs TACE:
	TACE: 455		LR: 81%, 68%, 63%		LR: 4/146 (2.7%)	Acute liver failure (20% vs 11%)
			TACE: 30%, 43%, 15%		TACE: 12/146 (8.2%)	Sig
			Sig		Sig	Biliary tract injury (6.8% vs 0%)
						Sig
Zhong et al[28]	LR: 660	NR	1-, 3- and 5-yr	NR	NR	NR
	TACE: 319		LR: 91%, 67%, 44%
			TACE: 83%, 35%, 17%
			Sig
Zhong et al[29]	LR: 257	LR: 42.9	1-, 3- and 5-yr	NR	LR vs TACE: 3.1% vs 3.7%	LR vs TACE: 28% vs 18.5%
	TACE: 135	TACE: 21	LR: 84%, 59%, 37%		No sig	Sig
		Sig	TACE: 69%, 29%, 14%
			Sig
			After propensity score analysis
			LR: 87%, 62%, 35%
			TACE: 77%, 44%, 20%
			Sig
Yin et al[31]	LR: 88	LR: 41	1-, 2- and 3-yr	NR	LR: 1/88 (1.1%)	NR
	TACE: 85	TACE: 14	LR: 76.1%, 63.5%, 51.5%
		Sig	TACE: 51.8%, 34.8%, 18.1%
			Sig

NR: Not reported; OS: Overall survival; DFS: Disease-free survival; Sig: Significant difference; LR: Patients with liver resection; TACE: Patients with trans-catheter arterial chemoembolization.